ABSTRACT Beyond neutralization, antibodies binding to their Fc receptors elicit several innate immune functions including antibody-dependent complement deposition (ADCD), antibody-dependent cell-mediated phagocytosis (ADCP), and antibody-dependent cell-mediated cytotoxicity (ADCC). These functions are beneficial, as they contribute to pathogen clearance; however, they also can induce inflammation. We tested the possibility that qualitative differences in SARS-CoV-2-specific antibody-mediated innate immune functions contribute to coronavirus disease 2019 (COVID-19) severity. We found that anti-S1 and anti-RBD antibodies from hospitalized COVID-19 patients elicited higher ADCD but lower ADCP compared to antibodies from nonhospitalized COVID-19 patients. Consistently, higher ADCD was associated with higher systemic inflammation, whereas higher ADCP was associated with lower systemic inflammation during COVID-19. Our study points to qualitative, differential features of anti-SARS-CoV-2 specific antibodies as potential contributors to COVID-19 severity. Understanding these qualitative features of natural and vaccine-induced antibodies will be important in achieving optimal efficacy and safety of SARS-CoV-2 vaccines and/or COVID-19 therapeutics.

IMPORTANCE A state of hyperinflammation and increased complement activation has been associated with coronavirus disease 2019 (COVID-19) severity. However, the pathophysiological mechanisms that contribute to this phenomenon remain mostly unknown. Our data point to a qualitative, rather than quantitative, difference in SARS-CoV-2-specific antibodies’ ability to elicit Fc-mediated innate immune functions as a potential contributor to COVID-19 severity and associated inflammation. These data highlight the need for further studies to understand these qualitative features and their potential contribution to COVID-19 severity. This understanding could be essential to develop antibody-based COVID-19 therapeutics and SARS-CoV-2 vaccines with an optimal balance between efficacy and safety.

KEYWORDS SARS-CoV-2, COVID-19, antibody, Fc-mediated functions, inflammation
functions are beneficial, as they contribute to pathogen clearance; however, they also can induce inflammation during viral infections (8). Here, we hypothesized that differential, qualitative features of SARS-CoV-2-specific antibodies contribute to COVID-19 severity. To test this hypothesis, we examined the ability of S1- and RBD-specific immunoglobulin G (IgG) from hospitalized and nonhospitalized COVID-19 patients (and controls) (Table S1) to elicit ADCD, ADCP, and ADCC.

Severe COVID-19 is associated with higher ADCD and lower ADCP compared to mild COVID-19. IgG from hospitalized COVID-19 patients elicited significantly higher ADCD against S1- and RBD-coated target cells compared to IgG from nonhospitalized individuals (Fig. 1a and b). In contrast, a higher fraction of IgG from nonhospitalized COVID-19 patients elicited ADCP activity above background (maximum value from the SARS-CoV-2-negative group) compared to hospitalized patients (Fig. 1c to e). S1-specific antibodies from hospitalized individuals induced significantly higher NK cell degranulation and intracellular cytokine production (a surrogate of ADCC) than did S1-specific antibodies from nonhospitalized individuals (Fig. 1f and g). In contrast, RBD-specific antibodies from nonhospitalized individuals induced significantly higher ADCC surrogates than did RBD antibodies from hospitalized individuals (Fig. 1h and i). These data suggest that hospitalized COVID-19 is associated with differential, qualitative features of SARS-CoV-2-specific antibodies. In particular, hospitalized COVID-19 is associated with a higher ability of antibodies to elicit complement deposition and a lower ability to elicit phagocytosis. These data are compatible with reports suggesting that complement immune system plays a significant negative role in coronavirus disease pathogenesis (9–11).

SARS-CoV-2 antibody titers correspond to ADCP but not ADCD or ADCC. We next sought to examine whether the differential levels of ADCD, ADCP, and ADCC between hospitalized and nonhospitalized patients can be simply explained by the titers of anti-S1 and anti-RBD antibodies. There was no significant difference in the titer of S1-specific antibodies between hospitalized and nonhospitalized patients in our cohort (Fig. 2a). When we examined S1-specific antibody titers in patients having ADCD, ADCP, or ADCC values below or above background levels (defined as the maximum values observed in the SARS-CoV-2-negative group), we found no difference in ADCD or ADCC but a significant difference in ADCP (Fig. 2b to d). Similar results were observed with RBD-specific antibodies (Fig. 2e to h). We also examined the ability of these IgGs to neutralize SARS-CoV-2 pseudovirus. There was no significant difference between the neutralization abilities of IgG from nonhospitalized and hospitalized patients in our cohort (Fig. 2i). However, half maximal inhibitory concentrations (IC50s) from the neutralization assay strongly correlated with higher ADCP (the higher the ability of IgGs to neutralize SARS-CoV-2 pseudovirus, the higher their ability to elicit ADCC) (see Fig. 2a in the supplemental material). These data indicate that the quantities of S1- or RBD-specific antibodies could explain the differences in ADCP activity between hospitalized and nonhospitalized patients (the higher the antibody titer, the higher the ADCP activity) but cannot fully explain the differences in ADCD or ADCC activity between hospitalized and nonhospitalized patients, suggesting that qualitative rather than quantitative properties of anti-SARS-CoV-2 antibodies associate with disease severity.

Anti-SARS-CoV-2 ADCD associates with higher inflammation. Given that complement activation can significantly contribute to inflammation-mediated tissue damage, including during COVID-19 (12, 13), we examined the relationship between the ADCD property of IgGc (as well as ADCP and ADCC) and 39 plasma markers of systemic inflammation and immune activation (a list is in Table S2). As expected, higher S1- and RBD-specific ADCD was associated with higher levels of several markers of inflammation and immune activation (Fig. 2j). In contrast, higher levels of S1- and RBD-specific ADCP were associated with lower levels of several inflammatory markers (Fig. 2j). Finally, ADCC exhibited an antigen-specific relationship with inflammation: anti-S1
specific ADCC exhibited negative correlations with inflammation, whereas anti-RBD exhibited positive correlations with inflammation (Fig. 2j). These data further point to the potentially detrimental effects of ADCD on COVID-19 pathogenesis.

Future studies will be needed to examine other antigen-specific antibodies including anti-N antibodies, as well as different antibody classes such as IgA and IgM. These
FIG 2 Antibody titers do not correlate with ability to elicit ADCC, which associates with higher systemic inflammation. (a) S1-specific antibody titers of the indicated groups. The Kruskal-Wallis test was used for statistical analysis. The horizontal dotted line indicates the maximum value from the SARS-CoV-2 (Continued on next page)
studies will also need to examine the mechanisms that underlie these differential, qualitative features. Antibody glycosylation and subclass have been shown as determinants of Fc-mediated innate immune functions (14). COVID-19 has been associated with high levels of proinflammatory IgG glycomic structures (15). Understanding how these glycomic features impact the different antibody-mediated innate immune functions during COVID-19 will be needed. Our sample size did not allow for addressing potential confounders. However, we observed no difference in antibody-mediated innate immune functions in individuals who received hydroxychloroquine, tocilizumab, or steroids compared with individuals who did not (Fig. S2, S3, and S4, respectively). Independent test sets from large cohorts from various geographic and demographic settings (including a wider range in age) will be needed in future studies. Finally, it will be important to understand how these antibody features impact the function of vaccine-mediated antibodies as well as therapeutic antibodies in order to achieve an optimal balance between neutralization and innate immune functions without inciting potential side effects.

In summary, our data suggest that differential, qualitative Fc-mediated antibody effector properties of anti-SARS-CoV-2 antibodies associate with COVID-19 severity. In particular, antibodies in individuals hospitalized with COVID-19 elicit higher levels of complement deposition compared to antibodies in individuals with mild COVID-19, in a manner linked to higher systemic inflammation. Understanding these qualitative properties will be important to develop COVID-19 therapeutics and SARS-CoV-2 vaccines with optimal efficacy and safety.

Ethics. All research protocols of the study were approved by the institutional review boards (IRB) at Rush University and The Wistar Institute. All human experimentation was conducted in accordance with the guidelines of the U.S. Department of Health and Human Services and those of the authors’ institutions.

Characteristics of the study cohort. We isolated IgG antibodies (using Pierce Protein G Spin Plate; Thermo Fisher) from 60 individuals who tested positive for SARS-CoV-2 (by PCR) and 20 negative controls. The 60 SARS-CoV-2-positive individuals were either outpatients (nonhospitalized; n = 20) or inpatients (hospitalized; n = 40) (Table S1). Individuals were selected to have a median age between 52.5 and 58.5 years to avoid age bias in disease outcome. The cohort was also chosen to be 45 to 60% female per group. Samples from hospitalized patients were collected when the patient was admitted. Samples from nonhospitalized patients were collected a median of 27 days after onset of COVID-19 symptoms. The concentration of purified IgG antibodies was determined using NanoDrop (absorbance at A280). Purified IgG antibodies were diluted with phosphate-buffered saline (PBS) and adjusted to a 1-mg/ml concentration.

ADCD measurements. Purified IgG antibodies were analyzed for their ability to fix complement on target cells. (ACE2)-CHO cells (4 × 10⁶) were pulsed with 20 μg biotinylated SARS-CoV-2 S1 or RBD proteins (Acro Biosystems) for 30 min at 37°C. Excess, unbound antigens were removed by washing cells once with complete medium. Twenty micrograms of IgG was added to the antigen-pulsed cells and incubated for another 30 min at 37°C. Freshly resuspended lyophilized guinea pig complement (Cedarlane) diluted 1:20 with Veronal buffer, 0.1% gelatin with calcium and magnesium

FIG 2 Legend (Continued)
(Boston BioProducts), was added to the cells for 2 h at 37°C. Following a wash with 1× PBS, cells were assessed for complement deposition by staining with goat anti-guinea pig C3a-fluorescein isothiocyanate (FITC) (MP Biomedicals). After fixing, cells were analyzed by flow cytometry, and ADCD is reported as median fluorescence intensity (MFI) of FITC+ cells.

**ADCP measurements.** Purified plasma IgG antibodies were analyzed for their ability to mediate phagocytosis of S1 and RBD antigen-coated beads. Biotinylated SARS-CoV-2 S1 and RBD proteins were combined with fluorescent Neutravidin beads (Life Technologies) overnight at 4°C. Excess, unconjugated antigens were removed by washing the beads twice with 0.1% PBS-bovine serum albumin (BSA). Beads were washed with 1 ml buffer and spun at 14,000 × g for 2 min at room temperature. Antigen-coated beads were resuspended in a final volume of 1 ml in PBS-BSA. Beads (10 µl) were added into each well of a round-bottom 96-well culture plate, after which 20 µg IgG was added to each well and incubated for 2 h at 37°C. A 200 µl suspension of THP-1 cells at 2.5 × 10^5 cells/ml was added to each well, for a total of 5 × 10^4 THP-1 cells per well. After mixing, the cell-bead mixtures were incubated overnight at 37°C. The following day, 100 µl of supernatant from each well was removed, and 100 µl of BD Cytofix was added to each well. Cells were analyzed by flow cytometry, and data collected were analyzed in FlowJo software. Phagoscores were computed by multiplying the percentage of fluorescent bead+ cells by the median fluorescence intensity (MFI) of bead+ cells.

**ADCC measurements.** ADCC induction was estimated by NK cell degranulation and intracellular cytokine production after exposure of antibodies to S1- and RBD-pulsed target cells. S1- or RBD-pulsed (ACE2)-CHO cells (2.5 × 10^6) were mixed with 20 µg IgG and incubated for 30 min at 37°C. Human NK cells (1 × 10^6) isolated from peripheral blood mononuclear cells (PBMC) using the EasySep human NK cell isolation kit (Stem Cell Technologies) were added to wells in the presence of CD107a phycoerythrin (PE) (BD) and Golgi Stop (BD). Pulsed (ACE2)-CHO immune complexes were then added to the wells, mixed, pelleted, and incubated at 37°C for 16 h. Postincubation, NK cell activation was detected by staining for CD56 peridinin chlorophyll protein (PerCP)-Cy5.5 (BD), gamma interferon (IFN-γ) (BD), and tumor necrosis factor (TNF) (BioLegend) and acquired via flow cytometry. Data are reported as the percentage of cells positive for the marker as indicated.

**Measurement of S1- and RBD-specific antibody titers.** S1- and RBD-specific antibody titers were measured in the plasma of the 80 individuals using the MSD V-Plex multiplex assay (Meso Scale Diagnostic).

**SARS-CoV-2 pseudovirus neutralization assay.** SARS-CoV-2-DeltaCT pseudovirus was produced using HEK-293T cells transfected with GeneJammer (Agilent) using IgE-SARS-CoV-2 S plasmid with a 19-amino-acid deletion at the C terminus (GenScript) and pNL4-3.Luc.R-E- plasmid (NIH AIDS reagent) at a 1:1 ratio. For setting up the pseudovirus neutralization assay, 10,000 (ACE2)-CHO cells per well were plated in 96-well plates in 100 µl medium and were rested at 37°C and 5% CO₂ for 24 h. On the following day, purified IgGs were serially diluted (from 100 µg/ml to 0.045 µg/ml). IgGs were incubated with a fixed amount of SARS-CoV-2-DeltaCT pseudovirus for 90 min at room temperature. After incubation, the IgG-virus mixture was added to the plated cells and was incubated in a standard incubator (37% humidity, 5% CO₂) for 72 h. After 72 h, cells were lysed using the Britelite Plus luminescence reporter gene assay system (Perkin-Elmer), and relative light units (RLU) were measured using a BioTek plate reader. The concentrations yielding 50% virus neutralization/inhibition (IC₅₀) were calculated and defined as the sample concentration at which RLU are reduced by 50% compared to RLU in virus control wells after subtraction of background RLU in cell control wells.

**Measurement of plasma markers of inflammation.** Plasma levels of granulocyte-macrophage colony-stimulating factor (GM-CSF), IFN-β, IFN-γ, interleukin-10 (IL-10), IL-13, IL-1β, IL-33, IL-4, IL-6, TNF-α, fractalkine, IL-12p70, IL-2, IL-21, IL-22, IL-23, IP-10, MCP-2, MIP-1α, SDF-1a, IFN-α2a, IL-12/IL-23p40, and IL-15 were determined using a
customized MSD U-Plex multiplex assay (Meso Scale Diagnostic). Plasma levels of C-reactive protein (CRP), galectin-1, galectin-3, galectin-9, growth differentiation factor-15 (GDF-15), soluble CD14 (sCD14), soluble CD163 (sCD163), lipopolysaccharide (LPS) binding protein (LBP), and FABP2/FABP were measured using enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems). The plasma level of zonulin was measured using an ELISA kit from MyBioSource. Levels of occludin were measured by ELISA (Biomatik). Plasma levels of Reg3A were measured by ELISA (RayBiotech). β-Glucan detection in plasma was performed using Limulus amebocyte lysate (LAL) assay (Glucatell kit; Associates of Cape Cod Inc.).

Statistical analysis. Kruskal-Wallis and Mann-Whitney U tests were used for unpaired comparisons. Chi-square test and Fisher’s exact test were used for binary comparisons. Spearman’s rank correlations were used for bivariate correlation analyses. Statistical analyses were performed in Prism 7.0 (GraphPad).

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

FIG S1, PDF file, 0.4 MB.
FIG S2, PDF file, 0.4 MB.
FIG S3, PDF file, 0.4 MB.
FIG S4, PDF file, 0.4 MB.
TABLE S1, PDF file, 0.04 MB.
TABLE S2, PDF file, 0.04 MB.

ACKNOWLEDGMENTS

A supplement supports this study to R01 DK123733 (R01 DK123733-01S1) for M. Abdel-Mohsen, A. Landay, and A. Keshavarzian and R24 AA026801-0251 for A. Keshavarzian. M. Abdel-Mohsen is also supported by The Foundation for AIDS Research (amfAR) Impact grant 109840-65-RGR, NIH grants (R01 AG062383, R01NS117458, R21 AI143385, and R21 AI129636), and the Penn Center for AIDS Research (P30 AI 045008).

We thank Rachel E. Locke for providing comments.

The authors have no competing interests.

M. Abdel-Mohsen conceived and designed the study. O. S. Adeniji, L. B. Giron, M. Purwar, and A. J. Kulkami carried out the experiments. N. F. Zilberstein, M. W. Shaikh, R. A. Balk, J. N. Moy, C. B. Forryth, Q. Liu, H. Dweep, A. Kossenkov, D. B. Weiner, A. Keshavarzian, and A. Landay selected study participants, analyzed data, and interpreted results. O. S. Adeniji and M. Abdel-Mohsen wrote the manuscript, and all authors edited it.

REFERENCES


